A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Latest Information Update: 02 Feb 2022
At a glance
- Drugs Pralatrexate (Primary)
- Indications Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Taiwan Mundipharma Pharmaceuticals
- 14 Dec 2021 Results of efficacy and safety of pralatrexate by using data from four trials including this trial presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 16 May 2017 New trial record